Close X
Friday, January 17, 2025
ADVT 
National

With Low Numbers Of New Cases, Ebola Vaccine Trials Fight Odds Of Success

The Canadian Press, 21 Jun, 2015 01:05 PM
    TORONTO — New Ebola infections in Guinea and Sierra Leone are down to a trickle. That means while there may still be time to prove if experimental Ebola vaccines protect against the dreaded disease, the chances of success are becoming slimmer.
     
    The teams trying to do that critical research know the odds are stacked against most of the trials that are underway.
     
    In fact, it could be that only one — a World Health Organization-led trial in Guinea testing a Canadian-designed vaccine — stands a real chance at coming up with an answer, if the case counts in West Africa continue at the current low level.
     
    The study involves vaccinating rings of people who are contacts of known cases to see if the vaccine prevents further spread. So far more than 70 rings out of a potential of 190 have been enrolled in the trial, testing a vaccine called rVSV-ZEBOV.
     
    Dr. Marie-Paule Kieny, who leads the WHO's efforts on development of Ebola vaccines and drugs, says if the vaccine is highly effective, the picture could come into focus relatively soon. The trial's independent overseers, its data and safety monitoring board, will be asked to review its status in the coming weeks.
     
    "So this is why it will be very important to let the DSMB at one point during summer ... look at the data and to tell us 'Well, you have enough' or 'Fine but keep going' or 'You will never demonstrate anything,'" Kieny says.
     
    If the trial proves rVSV-ZEBOV protects — or doesn't — and the outbreak still smoulders, the Guinea group will test a second vaccine. Kieny says work is underway to select which should be the second tested, a vaccine being developed by GSK or one being produced by Johnson and Johnson.
     
    Already a U.S. Centers for Disease Control-led trial in Sierra Leone has been adapted to ensure that it will produce useful information if, as feared, it cannot generate enough evidence to show whether the vaccine it is testing is effective.
     
    The Sierra Leone trial is also testing rVSV-ZEBOV, which was designed at Canada's National Microbiology Laboratory in Winnipeg. The vaccine is being developed by pharmaceutical giant Merck and NewLink Genetics, a biotech from Ames, Iowa.
     
    "It doesn't look very likely — although it's not impossible — that the trials will get at the efficacy of the vaccine," acknowledges Dr. Anne Schuchat, director of the CDC's Center for Immunization and Respiratory Diseases.
     
    The Sierra Leone trial to date has vaccinated more than 3,000 health-care professionals and other front-line Ebola response workers.
     
    In the event the trial can't reach a conclusion about the efficacy of the vaccine, the research team hopes to gather information that will help the U.S. Food and Drug Administration and other regulatory agencies consider another route to license the vaccine, called the animal rule.
     
    In exceptional circumstances when the efficacy of a drug or vaccine cannot be tested in people, regulators can substitute data from animal studies, pairing it with evidence that shows whether the product is safe to use.
     
    The Sierra Leone team will follow some of the people in their trial to see what happens to the levels of Ebola antibodies in their blood at various intervals post-vaccination.  
     
    "So we think it's too soon to be certain of whether (proving) efficacy will never be possible with our design," says Schuchat.
     
    "But we're trying to gather ... results that could potentially contribute to an alternate pathway to an accelerated licensure."
     
    A third trial testing rVSV-ZEBOV and the GSK vaccine started in Liberia early this year. Soon after Liberia's outbreak stopped, leaving that trial — led by the U.S. National Institute of Allergy and Infectious Diseases — unable to determine whether either vaccine works.
     
    Plans are being drawn up to move the trial to Guinea. But it's now estimated that the study will need to enrol roughly 200,000 people to prove if the vaccines work, given the low rate of new infections. The trial design is a classical one: Equal numbers of people will get one of the vaccines or a salt-water injection that will serve as a placebo.
     
    "I don't have a time frame but I'm hoping within one to two months we'd be able to start in Guinea," says Dr. Clifford Lane, clinical director for the National Institute for Allergy and Infectious Diseases. 
     
    Vaccinating that many people will take months, if not longer — a fact that leads some observers to question why the study is being pursued at this point.
     
    If the WHO study concludes by over the summer that rVSV-ZEBOV works, the new trial would have to be revised or abandoned. If it has been shown that one of the Ebola vaccines works, from an ethical point of view Ebola vaccines can no longer be studied against a placebo.
     
    As well, all involved in the Ebola outbreak hope transmission of the virus will be stopped long before this new study could get an answer.
     
    Lane understands that. Still, he says his group's approach is to push ahead until such time as it is clear the research cannot be done.
     
    "If in two months there are no cases that would be a great celebration," Lane says.
     
    "I'm being very serious. My hope is we never have to do this study. But as long as there's cases . . . we're going to work as hard as we can to get this launched."

    MORE National ARTICLES

    BC Ferries Drops Plan To Cut Service On Its Main Money-Making Routes

    BC Ferries Drops Plan To Cut Service On Its Main Money-Making Routes
    VICTORIA — BC Ferries says it will scuttle plans to trim services on its money-making routes between Vancouver Island and British Columbia's mainland and instead will find other ways to cut $4.9 million.

    BC Ferries Drops Plan To Cut Service On Its Main Money-Making Routes

    Shopify's Success Shines Bright Light On 'Renaissance' Of Ottawa's Tech Sector

    OTTAWA — Shopify Inc.'s successful stock-market debut is expected to reverberate well beyond the firm's Ottawa headquarters — and shine a spotlight on what some see as the second coming of the Canadian capital's tech sector.

    Shopify's Success Shines Bright Light On 'Renaissance' Of Ottawa's Tech Sector

    BC Regional District Won't Pay For Cleanup Of Demolished Site Where Allan Schoenborn Killed His Kids

    BC Regional District Won't Pay For Cleanup Of Demolished Site Where Allan Schoenborn Killed His Kids
    The Merritt, B.C., home where Allan Schoenborn stabbed his daughter and smothered his two sons has served as a loathsome reminder to the city since the killings in 2008.

    BC Regional District Won't Pay For Cleanup Of Demolished Site Where Allan Schoenborn Killed His Kids

    Police Discover Ontario Man Used Identity Of BC Boy Who Died In 1970s

    Police Discover Ontario Man Used Identity Of BC Boy Who Died In 1970s
    Police say a Caledonia, Ont., man who disappeared in 1992 took the name of a dead boy and lived under the assumed name until his death 10 years later.

    Police Discover Ontario Man Used Identity Of BC Boy Who Died In 1970s

    Supreme Court Orders New Trial For Alberta Men Who Made Sex Tapes Of 14-Year-Old Runaway Girls

    Supreme Court Orders New Trial For Alberta Men Who Made Sex Tapes Of 14-Year-Old Runaway Girls
    The Supreme Court of Canada has ordered a new trial in the case of two Edmonton men who made child pornography after videotaping two 14-year-old girls performing sex acts.

    Supreme Court Orders New Trial For Alberta Men Who Made Sex Tapes Of 14-Year-Old Runaway Girls

    Decades-Long Citizenship Battle Ends For Yukon Man Donovan McGlaughlin Who's Now Officially Canadian

    Decades-Long Citizenship Battle Ends For Yukon Man Donovan McGlaughlin Who's Now Officially Canadian
    The video showing Donovan McGlaughlin's Canadian citizenship ceremony in Dawson City, Yukon, is just two minutes and 11 seconds long but the elaborate script was decades in the making.

    Decades-Long Citizenship Battle Ends For Yukon Man Donovan McGlaughlin Who's Now Officially Canadian